Basic Reglan Information

• INN (International Nonproprietary Name): Metoclopramide.
• Brand Names Available In Canada (English): Not specified; metoclopramide in Canada is mostly supplied as generic formulations bearing a Drug Identification Number (DIN).
• ATC Code: A03FA01.
• Forms & Dosages: Tablets 5 mg and 10 mg; orally disintegrating tablets 5 mg and 10 mg; oral solution 5 mg/5 mL; injectable solution 5 mg/mL; nasal spray formulation available in some markets (Gimoti).
• Manufacturers In Canada (English): Not specified; international manufacturers include ANI Pharmaceuticals and Bausch Health (USA), Sandoz and Zentiva (EU), and several Indian manufacturers.
• Registration Status In Canada (English): Not specified in the provided data; product registrations are described for the USA, EU and other regions.
• OTC / Rx Classification: Prescription-only (Rx) in nearly all jurisdictions due to safety profile and risk of neurological adverse effects.

Latest Research Highlights

Are you worried about whether reglan really helps and what the risks are?

Recent Canadian pilot work and international trials from 2022 to mid‑2024 continue to show short‑term symptom improvement with metoclopramide for diabetic gastroparesis and selected refractory GERD.

Those studies repeatedly emphasise symptomatic relief in the first days to weeks, but lasting benefit beyond 2–8 weeks is uncertain.

Pharmacovigilance reports from Canada and the EU flag a disproportionate number of neurological adverse events in older adults and people with renal impairment.

Larger multicentre randomised controlled trials remain limited, while Canadian outpatient clinic pilots have explored low‑dose, short‑course strategies.

Health Canada advisories and international regulators have recommended restraint on long‑term or high‑dose prescribing, with ongoing monitoring expected into 2025.

Patient takeaways: favour the shortest effective course, document informed consent about extrapyramidal symptoms and tardive dyskinesia, and arrange active monitoring.

Clinical Effectiveness In Canada

Can reglan help your symptoms quickly?

Health Canada‑labelled metoclopramide products are used for symptomatic diabetic gastroparesis and for selected reflux cases when a prokinetic effect is needed.

Many patients notice relief of nausea, early satiety and bloating within days, though sustained benefit beyond a few weeks is uncertain.

Sustained use beyond 2–8 weeks is linked to higher cumulative risk of tardive dyskinesia, so clinicians aim for time‑limited courses.

Provincial formularies such as Ontario Drug Benefit, BC PharmaCare and RAMQ list metoclopramide with varying criteria, and coverage often requires diagnostic justification or time‑limited approvals.

In primary care and gastroenterology practice, metoclopramide is effective as a short‑course adjunct to dietary measures and improved glycaemic control in diabetic gastroparesis.

Monitoring best practice: document baseline neurological exam, review within 2–4 weeks, and reassess carefully before renewing beyond the recommended duration.

Indications And Expanded Uses

What is reglan officially for, and when do clinicians use it off‑label?

• Approved (Common): Symptomatic diabetic gastroparesis and selected cases of gastroesophageal reflux where a prokinetic is indicated.
• Off‑Label / Conditional: Short‑term peri‑procedural or chemotherapy nausea management under specialist care; some refractory nausea in pregnancy used with caution; selected paediatric nausea situations with weight‑based dosing.

Because of safety concerns, Canadian clinicians generally limit duration and reserve repeated or long‑term prescriptions for specialist review.

Patient note: use shared decision‑making and provide clear written instructions about signs of extrapyramidal symptoms, such as new involuntary movements or severe restlessness.

Composition And Brand Landscape

Which formulations of metoclopramide might you see at the pharmacy?

The active ingredient is metoclopramide (INN), ATC A03FA01, and it is sold globally under many brand names and generic labels.

In Canada, products are mostly generic and carry a DIN with bilingual labelling when marketed domestically.

Common dosage strengths you will encounter: 5 mg and 10 mg tablets, oral solution 5 mg/5 mL, and injectable 5 mg/mL ampoules or vials.

Pharmacies such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs typically stock oral forms, while hospital pharmacies usually maintain injectable stock, with rural availability varying.

Contraindications And Special Precautions

Who should not take reglan?

Absolute contraindications include pheochromocytoma, gastrointestinal obstruction/perforation/haemorrhage, prior tardive dyskinesia from metoclopramide, uncontrolled epilepsy, and known hypersensitivity.

Relative contraindications needing caution are Parkinson’s disease, significant renal or hepatic impairment, major depression, breastfeeding, and elderly or frail patients.

• Immediate Actions For Absolute Contraindications: Do not prescribe; refer to specialist and choose an alternative antiemetic or prokinetic strategy.
• Actions For Relative Contraindications: Consider dose reduction, more frequent follow‑up, and involve neurology or geriatrics when needed.

Canadian high‑risk groups include older adults and patients with chronic renal disease who have a higher risk of tardive dyskinesia and other neurological events.

Document culturally safe counselling and coordinate follow‑up with local health centres for Indigenous or remote patients who may have limited access to neurological assessment.

Note: metoclopramide can increase prolactin, so monitor for galactorrhea or menstrual disturbances when clinically relevant.

Dosage Guidelines

How is reglan dosed safely?

Typical adult dosing: for GERD 10–15 mg up to four times daily (max commonly cited 60 mg/day), and for diabetic gastroparesis 10 mg up to 4× daily with practical Canadian maxima often limited to 40 mg/day to reduce risk.

Paediatric dosing is weight‑based and neonates are generally excluded.

Elderly patients should start at lower doses with close monitoring, and renal impairment requires dose reduction proportional to GFR.

Counselling: if a dose is missed, take when remembered unless it is close to the next scheduled dose; do not double doses.

Interactions Overview

Which drugs should you avoid with reglan?

Key interactions increase the risk of extrapyramidal symptoms when combined with other dopamine antagonists such as antipsychotics or prochlorperazine.

CNS depressants like opioids and benzodiazepines may increase sedation when taken with metoclopramide.

Anticholinergic drugs can oppose the prokinetic effect and reduce efficacy.

Certain antidepressants and antipsychotics can lower seizure threshold and require caution.

Alcohol can potentiate sedation and worsen motor side effects, so advise avoidance or minimisation while taking metoclopramide.

Practical Canadian tip: reconciliation is important when patients buy medications across the border or from multiple prescribers; community pharmacy software and provincial e‑formulary tools help detect interactions.

Cultural Perceptions And Patient Habits

What do Canadian patients worry about when offered reglan?

Common concerns are neurological side effects reported in media and online forums, with many preferring short courses and non‑drug strategies first.

Bilingual labelling and culturally respectful counselling are expected, especially in francophone and Indigenous communities.

Rural and Northern patients often face access barriers to injectables and specialist follow‑up, so telehealth and nurse practitioner collaborations are useful.

• Patient Concerns: EPS, tardive dyskinesia, prolactin effects, and long‑term safety.
• Counselling Tips: Use clear plain language, offer translated materials, and coordinate care with local health centres for follow‑up.

Definitions: EPS refers to movement disorders such as acute dystonia and akathisia.

Tardive dyskinesia is a potentially irreversible involuntary movement disorder linked to prolonged dopamine antagonist exposure.

Prokinetic simply means a medication that stimulates gastrointestinal motility.

Availability And Pricing Patterns

How easy is it to get reglan and what does it cost in Canada?

Metoclopramide is prescription‑only in nearly all jurisdictions, and oral generics are widely available at major chains, while injectable availability is more variable.

Generics are generally low cost, but provincial coverage varies and may require prior authorisation for reimbursement.

Some patients cross the border to buy branded products in the USA, but importation rules and DIN requirements apply.

Online Canadian pharmacies may offer home delivery, but always verify credentials and the DIN on the product.

In our online pharmacy, reglan is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Comparable Medicines And Preferences

What are the alternatives to reglan and when are they preferred?

Domperidone, erythromycin and antiemetics such as ondansetron or prochlorperazine are used as alternatives depending on the clinical scenario.

Domperidone carries cardiac risks and its availability and use are restricted in many countries.

Erythromycin can be used as an off‑label prokinetic but has tachyphylaxis and tolerance issues.

When to choose alternatives: consider age, cardiac history, renal function, breastfeeding status and provincial formulary coverage.

For gastroparesis, many specialists in Canada prefer short metoclopramide courses or erythromycin in refractory cases, with specialist oversight for domperidone where available.

FAQ

• Is Reglan sold in Canada? Branded Reglan packaging is primarily seen in the USA and some EU markets; Canada supplies metoclopramide mostly as generics with a DIN—check the package DIN for local approval.
• How long can I safely take metoclopramide? Short courses of 2–8 weeks are typical; longer use raises the risk of tardive dyskinesia and needs specialist review.
• What side effects should I watch for? Watch for new involuntary movements, muscle stiffness, severe restlessness, excessive tiredness, or changes in breast milk; stop and seek medical review if these occur.
• Is it safe in pregnancy or breastfeeding? Use only after risk–benefit discussion with obstetric care; the drug passes into breast milk and breastfeeding decisions should be individualised.
• Where do I report adverse reactions in Canada? Report to Health Canada’s MedEffect system and notify your pharmacist or physician.

Guidelines For Proper Use

What steps should pharmacists and prescribers take before dispensing reglan?

• Confirm indication and document a time‑limited treatment plan.
• Check for absolute contraindications such as pheochromocytoma, GI obstruction, prior tardive dyskinesia, uncontrolled epilepsy, and hypersensitivity.
• Perform and document a baseline neurological exam and counsel on signs of EPS.
• Schedule follow‑up within 2–4 weeks and reassess before any renewal beyond the recommended duration.
• Adjust doses for renal or hepatic impairment and start lower in elderly patients.

Provide written bilingual counselling and a plain‑language warning card for patients to carry, especially when access to rapid neurology review is limited.

Storage: keep oral tablets and liquids at room temperature (20–25°C) and protect injectables from light per supplier instructions.

For rural patients, coordinate follow‑up with local clinics or telemedicine neurology if symptoms emerge, and record the DIN on the chart for audit and formulary checks.

Delivery Across Canada (English)